RxDoctor Payments Data

Sara Haverty, MD

Gynecology · Salisbury, MDNPI 1619966165

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 26 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 11 manufacturers, the largest accounting for just 17.0% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $163 and has fallen 87.5% since, to $20 in 2025. That places this record below the midpoint for gynecology clinicians in MD, where the typical reported total is $794.

$528in general payments, 2019–2025

Across 26 payments — averaging $20.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Aspira Women's Health Inc$90
  • AbbVie$74
  • Merck$67
  • Bayer$60
  • Astellas Pharma US Inc$47
  • Coopersurgical, Inc.$40
  • plus $151 from 5 others

What the payments were for

  • Food & beverage$528100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$528 in reported general payments places this provider in the 40th percentile of 79 gynecology providers in Maryland.

See all gynecology providers in Maryland

Medicare billing

Part B allowed, 2024
$782
Medicare patients
17
Services billed
19

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
PremarinEstrogens, Conjugated37$16,157
Estradiol71$5,950
YuvafemEstradiol13$2,363
ValacyclovirValacyclovir Hcl23$1,099
Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip32$632
Medroxyprogesterone Acetate26$455
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst16$177
Norethindrone Acetate11$41
Fluconazole14$31

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerPremarin$37$16,15737 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 79 gynecology providers in Maryland.

Other gynecology in Salisbury

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →